206 related articles for article (PubMed ID: 26730203)
1. Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression.
Phan NL; Trinh NV; Pham PV
Onco Targets Ther; 2016; 9():49-59. PubMed ID: 26730203
[TBL] [Abstract][Full Text] [Related]
2. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
3. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
[TBL] [Abstract][Full Text] [Related]
5. Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells.
Zhou Q; Ye M; Lu Y; Zhang H; Chen Q; Huang S; Su S
PLoS One; 2015; 10(8):e0136694. PubMed ID: 26305906
[TBL] [Abstract][Full Text] [Related]
6. Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?
Shima H; Yamada A; Ishikawa T; Endo I
Gland Surg; 2017 Feb; 6(1):82-88. PubMed ID: 28210556
[TBL] [Abstract][Full Text] [Related]
7. Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations.
Nguyen ST; Nguyen HL; Pham VQ; Nguyen GT; Tran CD; Phan NK; Pham PV
Onco Targets Ther; 2015; 8():323-34. PubMed ID: 25674007
[TBL] [Abstract][Full Text] [Related]
8. miR-205/RunX2 axis negatively regulates CD44
Zhang L; Liu L; Xu X; He X; Wang G; Fan C; Zheng Q; Li F
Am J Cancer Res; 2020; 10(6):1871-1887. PubMed ID: 32642297
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer.
Liu M; Liu Y; Deng L; Wang D; He X; Zhou L; Wicha MS; Bai F; Liu S
Mol Cancer; 2018 Feb; 17(1):65. PubMed ID: 29471829
[TBL] [Abstract][Full Text] [Related]
10. Genetic profiling of different phenotypic subsets of breast cancer stem cells (BCSCs) in breast cancer patients.
Zekri AN; Bahnassy A; Mourad M; Malash I; Ahmed O; Abdellateif MS
Cancer Cell Int; 2022 Dec; 22(1):423. PubMed ID: 36585652
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells.
Fan X; Chen W; Fu Z; Zeng L; Yin Y; Yuan H
Oncol Lett; 2017 Nov; 14(5):5069-5076. PubMed ID: 29142594
[TBL] [Abstract][Full Text] [Related]
12. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
[TBL] [Abstract][Full Text] [Related]
13. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
14. [Expression of breast cancer resistance protein and p-glycoprotein in residual breast cancer tissue after chemotherapy and its correlation with cancer stem cells].
Qu HB; Fan YM; Han ML; Luo HJ; Xie J; Liu H; Liu H; Wu CY; Tang WX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):171-6. PubMed ID: 23643006
[TBL] [Abstract][Full Text] [Related]
15. 5-aza-2'-Deoxycytidine enhances the radiosensitivity of breast cancer cells.
Wang L; Zhang Y; Li R; Chen Y; Pan X; Li G; Dai F; Yang J
Cancer Biother Radiopharm; 2013 Feb; 28(1):34-44. PubMed ID: 22917213
[TBL] [Abstract][Full Text] [Related]
16. Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells.
Guo Y; Engelhardt M; Wider D; Abdelkarim M; Lübbert M
Leukemia; 2006 Jan; 20(1):115-21. PubMed ID: 16307025
[TBL] [Abstract][Full Text] [Related]
17. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
Ma X; Zhang Y; Kang Y; Li L; Zheng W
Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic but not genomic variability confers phenotype of breast cancer stem cells.
Tong M; Deng Z; Yang M; Xu C; Zhang X; Zhang Q; Liao Y; Deng X; Lv D; Zhang X; Zhang Y; Li P; Song L; Wang B; Al-Dherasi A; Li Z; Liu Q
Cancer Commun (Lond); 2018 Sep; 38(1):56. PubMed ID: 30231942
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid receptor-β gene reexpression and biological activity in SHI-1 cells after combined treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid.
Xiang L; Wang R; Wei J; Qiu G; Cen J; Hu S; Xie X; Chen Z; Gu W
Acta Haematol; 2015; 133(3):279-86. PubMed ID: 25413479
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
Zuo X; Qin Y; Zhang X; Ning Q; Shao S; Luo M; Yuan N; Huang S; Zhao X
Oncol Rep; 2014 May; 31(5):2358-64. PubMed ID: 24676336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
